You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Building an evidentiary case for circulating GHBP as a biomarker for drug-associated stunting of growthSBC: ReveraGen BioPharma, Inc. Topic: NICHD
There is increasing interest in the use of biomarkers in clinical drug developmentwith much of thest Century Cures Act focused on encouraging this approachIdeallybiomarkers could provide and acute and objective read out of drug mechanism of actionpharmacodynamic biomarkersor prediction of later clinical benefit or harmsurrogate outcome measureHoweververy few biomarkers have been validated for rout ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's diseaseSBC: ASTROCYTE PHARMACEUTICALS INC. Topic: NIA
PROJECT SUMMARY Alzheimerandapos s diseaseADis an area of significant unmet need that creates a national burden of$billion annuallyAD is the leading cause of dementiaaffectingof Americans over the age ofDemographic shifts and the age related nature of AD will soon place this disease as the costliest health care expenditure in the U Swith a projected impact of $trillion per year byCurrent therapies ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: VELUM INC Topic: 300
PROJECT SUMMARY! Peptide therapeutics combine high potency and selectivityand engender fewer side effects than traditional small moleculesThis has fueled interest in peptides filling the gap between `biologicsandaposand small molecules as compounds that have key desired properties from both the other classesThere are however some challengesthe major one being susceptibility to enzyme catalyzed hyd ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: VELUM INC Topic: NIA
There is a world wide twin epidemic of obesity and TypeDiabetesT Dwith an urgent need to find effective new drug treatments for inducing weight lossStable derivatives of the endogenous glucoregulatory hormoneglucagon like peptideGLPare in clinical use for the treatment of T D but are of equally great interest as an emerging treatment of obesity and of age related neurodegenerative conditions inclu ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: SERPLUS TECHNOLOGY LLC Topic: NIAID
PROJECT SUMMARY Asthma exacerbations are a major cause of ER visits and hospitalizations with annual direct costs of approximately $billionyear in the USAViral infectionsin particular rhinoviralRVinfectionsare a major precipitant of asthma exacerbations in allergic asthmaticsAs there are overRV serotypes andfor nowno RV vaccinenovel strategies to inhibit RV induced airway inflammation are needed t ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: SERPLUS TECHNOLOGY LLC Topic: 200
The number of people with diabetes worldwide is predicted to increase frommillion intomillion inThe health care costs of treating the disease account forof the global health expenditure and continue to be a huge economic burdenIDF World AtlasTypediabetes mellitusT DMconstitutesof the disease burdenIt is an autoimmune diseasethought to be triggered by genetic or environmental factors in early child ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: INNOVAREGI LLC Topic: 400
AbstractThe current estimate of the number of human genes is aboutin contrast to the number of presumed proteinswhich likely exceeds one millionThis increased complexity is the result of post transcriptional and post translational modificationsPTMsoccurring at multiple sites and in a quantitative variable mannerThe overwhelming result is a combinatorially expanding complexity of proteoforms that i ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: IQ MEDICAL IMAGING LLC Topic: 102
Project SummaryAbstract Tumor imaging quantification is critical for diagnosisstagingand treatment evaluationand multi detector CTMDCTis the clinical imaging modality commonly used for patients diagnosed with hepatic malignancy because of its relatively low cost and wide availabilityConventional tumor quantification using either linear or volumetric measurement has demonstrated significant limitat ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: IQ MEDICAL IMAGING LLC Topic: 102
Project SummaryAbstract The neurofibromatosesNFsincluding NFNFand schwannomatosisare a group of autosomal dominant neurogenetic disorders characterized by a predisposition in virtuallyof patients to develop multiple nerve sheath tumorsThe determination of tumor burden on magnetic resonance imagingMRIis indispensable for the longitudinal management of NF patientswhich includes life long follow up f ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: TDA RESEARCH, INC. Topic: 102
Project Summary AbstractDevelopment of a Nerve Cuff Electrode from Soft and Elastomeric Conducting Wires STTR Phase I ApplicationPIBrady ClapsaddleTDA ResearchIncBio electronic interfaces are used in a wide array of applications for recording and providing electrical impulses to treat diseaseOne common interface device for the PNS is the cuff electrodeCurrent cuff electrodes have many failure mode ...STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health